Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 14 Endometrial Neoplasms 14 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Uterine Cervical Neoplasms 5 Head and Neck Neoplasms 5 Melanoma 4 Colonic Neoplasms 4 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Breast Neoplasms 3 Stomach Neoplasms 2 Osteosarcoma 2 Multiple Myeloma 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma 1

Interventions

Cyclophosphamide 132 Dexamethasone 106 Rituximab 70 fludarabine 64 Cytarabine 58 Lenalidomide 55 Gemcitabine 54 fludarabine phosphate 48 Bortezomib 47 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 41 Cisplatin 40 Peripheral Blood Stem Cell Transplantation 37 Filgrastim 37 pomalidomide 36 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 30 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 24 Nivolumab 24 Mycophenolic Acid 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡